申请人:Galley Guido
公开号:US20120245172A1
公开(公告)日:2012-09-27
The present invention relates to compounds of formula I
wherein A, B, X, Y, Ar, R
1
, R
2
, R′, m and n are as defined herein and to pharmaceutical active acid addition salts thereof.
Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
本发明涉及式I的化合物,其中A、B、X、Y、Ar、R1、R2、R′、m和n的定义如本文所述,并且涉及其药用活性酸盐。式I的化合物对痕量胺相关受体(TAARs)具有良好的亲和力,特别是对TAAR1。这些化合物可用于治疗抑郁症、焦虑障碍、双相情感障碍、注意力缺陷多动障碍(ADHD)、与压力相关的障碍、精神分裂症等精神障碍、帕金森病等神经系统疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、物质滥用、以及代谢障碍如进食障碍、糖尿病、糖尿病并发症、肥胖症、脂质代谢异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍、以及心血管疾病。